Loading...
Please wait, while we are loading the content...
Similar Documents
First-Line Immunochemotherapy Versus Palliative Chemotherapy Plus Definitive Radiation Therapy for de novo Metastatic Nasopharyngeal Carcinoma: A Matched Cohort Study
| Content Provider | SAGE Publishing |
|---|---|
| Author | Yang, Zhen-Chong Liu, Ting Chen, Yan-Zhou Guo, Chun-Yan Liu, Li-Ting Liu, Sai-Lan Chen, Qiu-Yan Mai, Hai-Qiang Guo, Shan-Shan |
| Copyright Year | 2022 |
| Abstract | The combined use of immune checkpoint inhibitors (ICIs) with palliative chemotherapy (PCT) is a promising first-line treatment for de novo metastatic nasopharyngeal carcinoma (mNPC). However, the efficacy of ICIs with PCT vs PCT with definitive radiation therapy (DRT) remain unclear.MethodsPatients with mNPC who received first-line immunochemotherapy (ICI + PCT) or PCT + DRT were included. Propensity score matching (PSM) was applied to balance potential confounders between patients who did and did not undergo DRT (at a ratio of 1:1). Progression free survival (PFS) and overall survival (OS) were compared between the 2 groups using a log-rank test and Cox proportional hazard model.ResultsAmong all participants, 149 received ICI + PCT. After PSM, 149 patients were included in the PCT + DRT group. First-line immunochemotherapy was associated with significantly improved PFS (median 9.0 months vs 12.0 months, P < .001) and OS (median 12.5 months vs 19.9 months, P < .001). Subgroup analysis revealed that tumor response to immunochemotherapy, metastatic organs, and number of metastatic sites potentially affected the efficacy of DRT after first-line immunochemotherapy.ConclusionCompared with PCT + DRT, first-line immunochemotherapy was associated with improved PFS and OS in patients with mNPC but not in patients with unfavorable tumor response and metastasis involving the liver, distant nodes, or multiple sites. |
| Related Links | https://journals.sagepub.com/doi/pdf/10.1177/10732748221124868?download=true |
| ISSN | 10732748 |
| Volume Number | 29 |
| Journal | Cancer Control (CCX) |
| e-ISSN | 15262359 |
| DOI | 10.1177/10732748221124868 |
| Language | English |
| Publisher | Sage Publications CA |
| Publisher Date | 2022-09-01 |
| Publisher Place | Los Angeles |
| Access Restriction | Open |
| Rights Holder | © The Author(s) 2022 |
| Subject Keyword | nasopharyngeal carcinoma radiation therapy immune-checkpoint inhibitor |
| Content Type | Text |
| Resource Type | Article |
| Subject | Hematology Oncology |
